The scientific study presented in the article is titled Treatment preferences for acute allergic reactions - a discrete choice experiment in Sweden. The study investigates the willingness to pay for a corticosteroid oral film among Swedish individuals with acute allergic reactions. The premise is that corticosteroids are a common treatment for acute allergic reactions, and the oral film offers an alternative to corticosteroid tablets, which can be difficult to administer in an acute situation. The study results show a high willingness to pay among patients.

The study is part 2 of a larger survey study conducted in collaboration with IHE, the Institute for Health Economics. Part 1 focuses on treatment preferences among Swedish patients with acute allergic reactions and was published in April 2024 in the scientific peer-reviewed journal World Allergy Organization Journal.

"Part 1 of the study clarifies that there is a significant and clear patient need for a medication like Zeqmelit®. The article on part 2 will increase awareness that there is also a strong willingness to pay for Zeqmelit® among patients," says Jonas Jönmark, CEO of AcuCort.

"It is a significant recognition for the treatment with Zeqmelit® that AcuCort's study on the willingness to pay among allergy patients is featured in a well-respected scientific journal that reaches a large portion of our direct target audience. The timing is also perfect as the launch of Zeqmelit® is planned for this summer," says Jonas Jönmark.

The article in the Journal of Health Economics and Outcomes Research is expected to be published in the summer of 2024.